Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.

摘要: Background: The estrogen receptor (ER), progesterone (PR), and HER2 profile of a primary breast carcinoma plays significant role in patient management treatment. Because the increasing utilization neoadjuvant chemotherapy or hormone therapy, surgically-resected carcinomas often show marked treatment effect. aim this study was to compare immunohistochemical (IHC) profiles (ER, PR, HER2, FISH) before after assess subsequent effects on status. Design: Primary from 38 female patients treated with therapy needle core biopsy fine aspiration diagnosis were included. Histologic data collected for each case, including site, type, grade, tumor size (cm), pre- post- IHC panel HER2), fluorescence in-situ hybridization (FISH) HER2. Results: Of studied, 45 % positive ER by both (P=1.00). studies PR these showed 37% positivity pre-neoadjuvant 21% post-treatment (p=0.03). For 37 IHC, 32% pre-treatment, 22% (P = 0.20). 7 patients, FISH 71% pre-therapy 57% (P=0.32). Conclusions: Profiles ER, not significantly different chemotherapy. Further investigation is warranted reproducibility technique investigate clinical implications loss status patients.